Journey MedicalDERM
DERM
About: Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
Employees: 41
0
Funds holding %
of 7,327 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
143% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 7
102% more capital invested
Capital invested by funds: $14.8M [Q4 2024] → $30M (+$15.2M) [Q1 2025]
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
4.27% more ownership
Funds ownership: 25.44% [Q4 2024] → 29.71% (+4.27%) [Q1 2025]
3% more funds holding
Funds holding: 37 [Q4 2024] → 38 (+1) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$12
72%
upside
Avg. target
$12
72%
upside
High target
$12
72%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
B. Riley Securities Kalpit Patel | 72%upside $12 | Buy Maintained | 30 Jul 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SCOTTSDALE, Ariz., July 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that 65% of the 187 million commercial lives in the United States now have pharmacy benefit coverage for Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release), the Company's recently launched treatment for the inflammatory lesions of rosacea in adults.
Neutral
GlobeNewsWire
1 month ago
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution.
Neutral
GlobeNewsWire
1 month ago
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent of body weight differences when treating rosacea Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent of body weight differences when treating rosacea
Neutral
GlobeNewsWire
1 month ago
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz.
Neutral
Seeking Alpha
2 months ago
Journey Medical Corporation (DERM) Q1 2025 Earnings Call Transcript
Journey Medical Corporation (NASDAQ:DERM ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and Chief Executive Officer Joseph Benesch - Chief Financial Officer Louis Donati - Director of Market Access Srinivas Sidgiddi - Vice President, Research and Development Ramsey Alloush - Chief Operating Officer and General Counsel Conference Call Participants Scott Henry - AGP Kalpit Patel - B. Riley Securities Thomas Flatten - Lake Street Capital Markets Operator Ladies and gentlemen, thank you for standing by.
Positive
Zacks Investment Research
2 months ago
Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.53 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz.
Neutral
GlobeNewsWire
2 months ago
Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025
Company to host conference call to discuss financial results and provide a corporate update on May 14, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 14, 2025 at 4:30 p.m. ET
Positive
Zacks Investment Research
3 months ago
Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last?
Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Negative
Benzinga
3 months ago
Top 3 Health Care Stocks That May Crash In Q2
As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Charts implemented using Lightweight Charts™